ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AZN Astrazeneca Plc

10,678.00
-64.00 (-0.60%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -64.00 -0.60% 10,678.00 10,688.00 10,690.00 10,780.00 10,674.00 10,756.00 1,773,970 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 27.83 165.72B

Seres Therapeutics Shares Up 15% on AstraZeneca Collaboration

11/03/2019 2:15pm

Dow Jones News


Astrazeneca (LSE:AZN)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Astrazeneca Charts.

By Chris Wack

 

Shares of Seres Therapeutics Inc. (MCRB) jumped almost 15% to $5.88 after announcing a collaboration with AstraZeneca PLC (AZN).

The Cambridge, Mass.-based novel drug company said Monday that the collaboration is focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer.

Seres' SER-401, an investigational microbiome therapeutic, may be studied in combination with AstraZeneca compounds targeting various cancers.

Under the terms of the exclusive collaboration, AstraZeneca will provide Seres with $20 million in three equal installments over two years, with the first payment due at the start of the agreement. In addition, AstraZeneca will also reimburse Seres for research activity related to the collaboration. Seres will maintain rights to oncology targeted microbiome therapeutic candidates, and AstraZeneca will obtain the option to negotiate for rights to those programs and other inventions arising out of the collaboration.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

March 11, 2019 10:00 ET (14:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart

Your Recent History

Delayed Upgrade Clock